SCHEMBL8700102

SCHEMBL8700102

CC(=O)Cc1ccc2oc(C(=O)O)c(C)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.60
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 6/20 0.53
GPR35 Q9HC97 1/20 0.53
HPGD P15428 6/20 0.52
GAA P10253 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TSHR P16473 1/20 0.48
RAB9A P51151 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
RECQL P46063 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
NPC1 O15118 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551841 0.86 MCL1 (0.57) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL1065625 0.84 MCL1 (0.61) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL937858 0.81 MCL1 (0.58) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL7339528 0.78 KDM4E (0.55) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL1065472 0.78 MCL1 (0.71) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL10735951 0.77 MCL1 (0.65) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL5287590 0.76 MCL1 (0.69) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL4615856 0.75 MCL1 (1.00) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL4310466 0.75 MCL1 (0.67) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL3617512 0.75 MCL1 (0.67) MCL1KDM4EALDH1A1GPR35HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5767133-A Secondary amines as antidiabetic and antiobesity agents PFIZER INC. (US) 1998-06-16 US disclosed
EP-0703911-B1 SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS PFIZER (US) 1997-07-02 EP disclosed
US-5627200-A β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia PFIZER INC (US) 1997-05-06 US disclosed
EP-0703911-A1 SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS PFIZER (US) 1996-04-03 EP disclosed
WO-1994029290-A1 SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS PFIZER INC. (US) 1994-12-22 WO disclosed